Management of SLE-ILD

First-Line Treatment Strategy

The American College of Rheumatology recommends initiating treatment with glucocorticoids combined with mycophenolate, azathioprine, rituximab, or cyclophosphamide as first-line therapy for SLE-ILD, with mycophenolate being the preferred immunosuppressive agent 1, 2
Short-term glucocorticoids (≤3 months) are conditionally recommended for SLE-ILD, distinguishing it from SSc-ILD where glucocorticoids are strongly contraindicated 1, 2
Oral prednisone is commonly used for stable disease, while intravenous pulse methylprednisolone (250-1000 mg daily for 1-3 days) is reserved for acute onset or severe ILD 1, 3
The goal is to minimize chronic glucocorticoid exposure to less than 7.5 mg/day prednisone equivalent and withdraw when possible 3
Mycophenolate is the preferred first-line immunosuppressive therapy for SLE-ILD, typically dosed at 1000-1500 mg twice daily with CBC monitoring every 2-4 months 1, 2, 4

Progression is defined as: FVC decline ≥10% predicted, OR FVC decline 5-10% predicted plus worsening respiratory symptoms or increased fibrosis on HRCT, OR worsening symptoms plus increased fibrosis—all within 24 months 2
Switch to or add mycophenolate, rituximab, cyclophosphamide, or nintedanib if not already used as first-line agents 1, 6, 5
Tocilizumab is conditionally recommended for progressive SLE-ILD despite first-line treatment 6, 5, 4
Avoid long-term glucocorticoids for progressive disease given substantial adverse effects without proven long-term efficacy 1, 6, 4

Pulse intravenous methylprednisolone is conditionally recommended as first-line treatment for rapidly progressive disease 6, 5, 7
Upfront combination therapy (double or triple therapy) is conditionally recommended over monotherapy for rapidly progressive ILD 6, 5, 7, 4

Perform PFTs including FVC and DLCO every 3-6 months to assess disease progression 4
High-resolution CT scanning at baseline and annually (or with significant PFT changes) is recommended to evaluate disease progression 4

Do not rely on long-term high-dose glucocorticoids for maintenance therapy—they increase morbidity without proven efficacy for chronic ILD management 1, 6, 4
Prompt initiation of immunomodulatory agents expedites glucocorticoid tapering 3

Management decisions should involve collaboration between rheumatologists and pulmonologists to balance control of systemic lupus activity with ILD progression 4

Optimal medical management is conditionally recommended over referral for stem cell or lung transplantation as first-line treatment 1, 2, 5
For rapidly progressive disease, early referral for lung transplantation is conditionally recommended over later referral after progression on optimal medical management 6, 5, 7